tbuckley/cabot-search huggingface dataset:
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3
Authors: Ishmael A. Jaiyesimi, Dwight H. Owen, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Navneet Singh
Journal: Journal of Clinical Oncology (2023)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in theASCO Guidelines Methodology Manual. ASCO Living Guidelines follow theASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1andAppendix 2). Updates are published regularly and can be found athttps://ascopubs.org/nsclc-non-da-living-guideline.
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
Authors: Jacqueline T. Brown, Bassel Nazha, Mehmet Asim Bilen
Journal: Journal of Clinical Oncology (2023)

The currently enrolling SAMETA, in which MET-driven tumors are randomly assigned to receive savolitinib plus durvalumab versus durvalumab versus sunitinib, arose directly from CALYPSO and is the only biomarker-based, randomized, phase III clinical trial in RCC (ClinicalTrials.gov
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3
Authors: Ishmael A. Jaiyesimi, Dwight H. Owen, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Navneet Singh
Journal: Journal of Clinical Oncology (2023)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in theASCO Guidelines Methodology Manual. ASCO Living Guidelines follow theASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1andAppendix 2). Updates are published regularly and can be found athttps://ascopubs.org/nsclc-da-living-guideline.
A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial
Authors: Gabriela Ilie, Ricardo Rendon, Ross Mason, Cody MacDonald, Michael J. Kucharczyk, Nikhilesh Patil, David Bowes, Greg Bailly, David Bell, Joseph Lawen, Michael Ha, Derek Wilke, Peter Massaro, Jeffery Zahavich, George Kephart, Robert David Harold Rutledge
Journal: European Urology (2023)

Although survival rates for newly diagnosed prostate cancer patients are very high, most of them will likely suffer significant treatment-related side effects, depression, or anxiety, affecting their quality of life.
Complex regulation of alarmins S100A8/A9 and secretion via gasdermin D pores exacerbates autoinflammation in familial Mediterranean fever
Authors: Selina K. Jorch, Annika McNally, Philipp Berger, Jonas Wolf, Kim Kaiser, Andrian Chetrusca Covash, Stefanie Robeck, Isabell Pastau, Olesja Fehler, Saskia-L. Jauch-Speer, Sven Hermann, Michael Schäfers, Hanne Van Gorp, Apurva Kanneganti, Joke Dehoorne, Filomeen Haerynck, Federica Penco, Marco Gattorno, Jae Jin Chae, Paul Kubes, Mohamed Lamkanfi, Andy Wullaert, Markus Sperandio, Thomas Vogl, Johannes Roth, Judith Austermann
Journal: Journal of Allergy and Clinical Immunology (2023)
Persistent dysregulation of cellular immunity following COVID-19 recovery despite minimal post-COVID-19 sequelae manifestation
Authors: Denise Utami Putri, Chun-Kai Huang, Tsong-Yih Ou, Chiou-Feng Lin, Ming-Che Lee, Ching-Sheng Hung, Chih-Hsin Lee
Journal: Journal of Infection (2023)
Outbreak of indeterminate acute liver failure in children with adenoviraemia – Not a new disease
Authors: Barath Jagadisan, Anita Verma, Maesha Deheragoda, Akash Deep, Tassos Grammatikopoulos, Malur Sudhanva, Sanjay Bansal, Nedim Hadzic, Sunitha Vimalesvaran, Nigel Heaton, Anil Dhawan
Journal: Journal of Hepatology (2023)
A retrospective study of small-diameter invasive melanomas: Metastasis at diagnosis and 9-year follow-up
Authors: Clio Dessinioti, Michaella Plaka, Katerina Kypreou, Aravella Stergiopoulou, Maria Kostaki, Efthymia Soura, Vasiliki Chasapi, Angelliki Befon, Alexander J. Stratigos
Journal: Journal of the American Academy of Dermatology (2023)
Mpox in people with advanced HIV infection: a global case series
Authors: Oriol Mitjà, Andrea Alemany, Michael Marks, Jezer I Lezama Mora, Juan Carlos Rodríguez-Aldama, Mayara Secco Torres Silva, Ever Arturo Corral Herrera, Brenda Crabtree-Ramirez, José Luis Blanco, Nicolo Girometti, Valentina Mazzotta, Aniruddha Hazra, Macarena Silva, Juan José Montenegro-Idrogo, Kelly Gebo, Jade Ghosn, María Fernanda Peña Vázquez, Eduardo Matos Prado, Uche Unigwe, Judit Villar-García, Noah Wald-Dickler, Jason Zucker, Roger Paredes, Alexandra Calmy, Laura Waters, Cristina Galvan-Casas, Sharon Walmsley, Chloe M Orkin, Viviana Leiro, Lucila Marchetta, Patricia Fernandez Pardal, María Inés Figueroa, Pedro Cahn, Katharina Grabmeier-Pfistershammer, Agnes Libois, Laurens Liesenborghs, Beatriz Grinsztejn, Mauro Schechter, Alberto dos Santos de Lemos, Alvaro Furtado Costa, Simone Queiroz Rocha, José Valdez Madruga, Darrell H. S. Tan, Sharmistha Mishra, Shreya Shah, Camila Jorquera, Alberto Castillo, Mauricio Carrión, Nelson Cevallos, Romain Palich, Valerie Pourcher, Emma Rubenstein, Pascal Migaud, Christoph Boesecke, Christian Hoffmann, Konstantinos Protopapas, Silvia Nozza, Anna Maria Cattelan, Cristina Mussini, Antonella d'Arminio Monforte, Raúl Adrian Cruz Flores, Edgar Pérez Barragán, Alma Leticia Rodríguez Guzmán, Dimie Ogoina, Nneka Marian Chika-Igwenyi, Onyeaghala Chizaram, Jenny Valverde López, Angelica García Tello, Maria Ubals, Martí Vall, Adrià Mendoza, Clara Suñer, Bonaventura Clotet, Jordi Bechini, Jose A Lepe, M. Dolores Navarro-Amuedo, Jose Ignacio Bernadino, Alba Català, Eloy José Tarín Vicente, Borja González Rodríguez, Sergi Rodriguez-Mercader, Francisca Sánchez-Martinez, Esperanza Cañas-Ruano, Laura Parra-Navarro, Finn Filén, Carmen Tallón de Lara, Dominique Braun, Vanja Piezzi, Michael Burkhard, Helen Kovari, Anja Mönch, Jake Dunning, Pedro Simoes, Achyuta Nori, Sarah Keegan, John P Thornhill, Vanessa Apea, Teymur Noori, Joyce L. Jones, Seth Judson, Elizabeth A. Gilliams, Matthew M. Hamill, Jeanne Keruly, Andrés F. Henao Martínez, Aung Lin, Jessica So, Kusha Davar, Diana Villareal, Miguel Tapia Paredes
Journal: The Lancet (2023)
Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation
Authors: Robert N. Helsley, Se-Hyung Park, Hemendra J. Vekaria, Patrick G. Sullivan, Lindsey R. Conroy, Ramon C. Sun, María del Mar Romero, Laura Herrero, Joanna Bons, Christina D. King, Jacob Rose, Jesse G. Meyer, Birgit Schilling, C. Ronald Kahn, Samir Softic
Journal: Journal of Hepatology (2023)
Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase
Authors: Eric Yuk Fai Wan, Boyuan Wang, Sukriti Mathur, Cheyenne I. Ying Chan, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Philip Hei Li, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan
Journal: Journal of Infection (2023)
Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling
Authors: Yu Song, Jiayi Wei, Rong Li, Ruifeng Fu, Pei Han, Heming Wang, Guangcong Zhang, Shuyu Li, Sinuo Chen, Zhiyong Liu, Yicheng Zhao, Changfeng Zhu, Jimin Zhu, Shuncai Zhang, Hao Pei, Jiefei Cheng, Jian Wu, Ling Dong, Guangqi Song, Xizhong Shen, Qunyan Yao
Journal: Hepatology (2023)

Background and Aims: Liver fibrosis is a leading indicator for increased mortality and long-term comorbidity in NASH. Activation of HSCs and excessive extracellular matrix production are the hallmarks of liver fibrogenesis. Tyrosine kinase receptor (TrkB) is a multifunctional receptor that participates in neurodegenerative disorders. However, paucity of literature is available about TrkB function in liver fibrosis. Herein, the regulatory network and therapeutic potential of TrkB were explored in the progression of hepatic fibrosis. Methods and Results: The protein level of TrkB was decreased in mouse models of CDAHFD feeding or carbon tetrachloride-induced hepatic fibrosis. TrkB suppressed TGF-β-stimulated proliferation and activation of HSCs in 3-dimensional liver spheroids and significantly repressed TGF-β/SMAD signaling pathway either in HSCs or in hepatocytes. The cytokine, TGF-β, boosted Nedd4 family interacting protein-1 (Ndfip1) expression, promoting the ubiquitination and degradation of TrkB through E3 ligase Nedd4-2. Moreover, carbon tetrachloride intoxication-induced hepatic fibrosis in mouse models was reduced by adeno-associated virus vector serotype 6 (AAV6)–mediated TrkB overexpression in HSCs. In addition, in murine models of CDAHFD feeding and Gubra-Amylin NASH (GAN), fibrogenesis was reduced by adeno-associated virus vector serotype 8 (AAV8)–mediated TrkB overexpression in hepatocytes. Conclusion: TGF-β stimulated TrkB degradation through E3 ligase Nedd4-2 in HSCs. TrkB overexpression inhibited the activation of TGF-β/SMAD signaling and alleviated the hepatic fibrosis both in vitro and in vivo . These findings demonstrate that TrkB could be a significant suppressor of hepatic fibrosis and confer a potential therapeutic target in hepatic fibrosis.
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Shuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, Vinita Takiar, Maria Lehn, Ilaina Monroe, Sarah Palackdharry, Nicky Kurtzweil, Roman Jandarov, Nusrat Harun, Trisha M. Wise-Draper
Journal: Clinical Cancer Research (2023)

The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and suppression of antitumor immunity. We hypothesized that adding an immune-checkpoint inhibitor (ICI) could overcome this and lead to an enhanced antitumor response.A phase II study of cetuximab and durvalumab in metastatic HNSCC was conducted. Eligible patients had measurable disease. Patients who had received both cetuximab and an ICI were excluded. The primary endpoint was objective response rate (ORR) by RECIST 1.1 at 6 months.As of April 2022, 35 patients enrolled, of whom 33 received at least 1 dose of durvalumab and were included in the response analysis. Eleven patients (33%) had received prior platinum-based chemotherapy, 10 an ICI (30%), and 1 patient (3%) cetuximab. ORR was 39% (13/33) with a median duration of response of 8.6 months [95% confidence interval (CI): 6.5-16.8]. Median progression-free and overall survivals were 5.8 months (95% CI: 3.7-14.1) and 9.6 months (95% CI: 4.8-16.3), respectively. There were 16 grade 3 treatment-related adverse events (TRAE) and one grade 4 TRAE, with no treatment-related deaths. Overall and progression-free survival did not correlate with PD-L1 status. NK cell cytotoxic activity was increased by cetuximab and further increased with the addition of durvalumab in responders.The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.
Contents
Authors: B Zeuzem, P Sangro, D Povero, W Miesbach, G Foster, F Peyvandi, V Ajmera, S Cepin, K Tesfai, H Hofflich, K Cadman, S Lopez, E Madamba, R Bettencourt, L Richards, C Behling, C Sirlin, R Loomba, V Ratziu, S Harrison, V Loustaud-Ratti, C Bureau, E Lawitz, M Abdelmalek, N Alkhouri, S Francque, H Girma, R Darteil, H Couchoux, M Wolf, A Sanyal, J Vonderscher, P Scalfaro, G Cholankeril, J Kramer, J Chu, X Yu, M Balakrishnan, L Li, H El-Serag, F Kanwal, A Louvet, V Bourcier, I Archambeaud, L D'alteroche, C Chaffaut, F Oberti, C Moreno, D Roulot, T Dao, R Moirand, J.-C Duclos-Vallée, O Goria, E Nguyen-Khac, S Pol, N Carbonell, J Gournay, L Elkrief, I Fouchard-Hubert, S Chevret, N Ganne-Carrié, E Gane, P Dunbar, A Brooks, F Zhang, D Chen, J Wallin, N Van Buuren, P Arora, S Fletcher, S Tan, J Yang, A Gaggar, S Kottilil, L Tang, -F Yip, -S Wong, J Lai, -T Lai, -K Hui, L Liang, Y.-K Tse, -Y Chan, -H Wong, W.-M Choi, -H Wong, W Kim, L Yee, C Brooks-Rooney, T Curteis, H Cant, C.-H Chen, C.-Y Chen, Y.-H Huang, Y.-J Jin, D Jun, J.-W Kim, N Park, C.-Y Peng, H Shin, J Shin, Y.-H Yang, Y.-S Lim, S Chen, Z Lu, H Jia, B Yang, C Liu, S Zhang, Z Wang, L Yang, S Li, J Li, C Yang, F Trovato, R Zia, F Artru, S Mujib, E Jerome, A Cavazza, M Coen, I Wilson, E Holmes, P Morgan, A Singanayagam, C Bernsmeier, S Napoli, W Bernal, J Wendon, R Miquel, K Menon, V Patel, J Smith, S Atkinson, E Triantafyllou, M Mcphail, X Zhang, J Song, Y Zhang, B Wen, L Dai, R Xi, Q Wu, Y Li, X Luo, X Lan, Q He, W Luo, Q Lai, Y Ji, L Zhou, T Qi, M Liu, F Zhou, W Wen, H Li, Z Liu, Y Chen, Y Zhu, J Huang, X Cheng, M Tu, J Hou, H Wang, J Chen, P Burra, F Tacke, S Zeuzem, B Sangro, P Angeli, J Kellum, M Nadim, D Samuel, R Morikawa, N Nakamoto, T Amiya, P.-S Chu, Y Koda, T Teratani, T Suzuki, Y Kurebayashi, A Ueno, N Taniki, K Miyamoto, A Yamaguchi, S Shiba, T Katayama, K Yoshida, Y Takada, R Ishihara, H Ebinuma, M Sakamoto, T Kanai, S.-T Cheng, J.-L Hu, J.-H Ren, H.-B Yu, S Zhong, V Wong, B Kwan Law, W.-X Chen, H.-M Xu, Z.-Z Zhang, X.-F Cai, Y Hu, W.- L Zhang, Q.-X Long, F Ren, H.-Z Zhou, A.-L Huang, J Howell, A Pedrana, S Schroeder, N Scott, L Aufegger, R Atun, R Baptista-Leite, G Hirnschall, E 't Hoen, S Hutchinson, J Lazarus, L Olufunmilayo, R Peck, M Sharma, A Sohn, A Thompson, M Thursz, D Wilson, M Hellard, S.-Y Cai, D Yu, C Soroka, J Wang, J Boyer, D Chand, F Mohr, H Mcmillan, F Tukov, K Montgomery, A Kleyn, R Sun, S Tauscher-Wisniewski, P Kaufmann, G Kullak-Ublick, T Marjot, A Moon, J Cook, S Abd-Elsalam, C Aloman, M Armstrong, E Pose, E Brenner, T Cargill, M.-A Catana, R Dhanasekaran, A Eshraghian, I García-Juárez, U Gill, P Jones, J Kennedy, A Marshall, C Matthews, G Mells, C Mercer, P Perumalswami, E Avitabile, X Qi, F Su, N Ufere, Y Wong, M.-H Zheng, E Barnes, A Barritt, G Webb, M Tonon, S Rosi, C Gambino, S Piano, V Calvino, A Romano, A Martini, P Pontisso
Journal: Journal of Hepatology (2023)
JHEP at a glance (March 2023)
Authors: Veeral Ajmera, Sandra Cepin, Kaleb Tesfai, Cynthia Behling, Claude Sirlin, Rohit Loomba, Vlad Ratziu, Stephen Harrison, Véronique Loustaud-Ratti, Arun Sanyal, Jacky Vonderscher, Pietro Scalfaro, George Cholankeril, Jennifer Kramer, Jinna Chu, Liang Li, Hashem El-Serag, Fasiha Kanwal
Journal: Journal of Hepatology (2023)
Table of Contents
Authors: Li-Li Hsiao, Kavya Shah, Adrian Liew, Dina Abdellatif, Alessandro Balducci, Ágnes Haris, Latha Kumaraswami, Vassilios Liakopoulos, Siu-Fai Lui, Ifeoma Ulasi, Robyn Langham, Tungki Pratama Umar, Nityanand Jain, Henri Open, Tilman Drueke, Ziad Massy, Steven Chadban, Julian Singer, P Coates, Kevin Burns, Adrianna Douvris, Anne Mühlig, Jun Oh, Tobias Huber, Sanjeev Sethi, Benjamin Madden, Sabine Karam, Mohamad Haidous, Virginie Royal, Nelson Leung, Fabio Fernandes-Rosa, Sheerazed Boulkroun, Bakhta Fedlaoui, Marguerite Hureaux, Simon Travers-Allard, Tom Drossart, Judith Favier, Maria-Christina Zennaro
Journal: Kidney International (2023)
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
Authors: Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L Hyrich, Ann W Morgan, Anthony G Wilson, John D Isaacs, Darren Plant, Anne Barton
Journal: Annals of the Rheumatic Diseases (2023)

Objectives The inflammatory protein calprotectin (MRP8/14) has been identified as a promising biomarker of treatment response in rheumatoid arthritis (RA). Our aim was to test MRP8/14 as a biomarker of response to tumour necrosis factor (TNF)-inhibitors in the largest RA cohort to date and to compare with C-reactive protein (CRP). Methods Serum MRP8/14 was measured in 470 patients with RA about to commence treatment with adalimumab (n=196) or etanercept (n=274). Additionally, MRP8/14 was measured in the 3-month sera of 179 adalimumab-treated patients. Response was determined using European League against Rheumatism (EULAR) response criteria calculated using the traditional 4-component (4C) DAS28-CRP and alternate validated versions using 3-component (3C) and 2-component (2C), clinical disease activity index (CDAI) improvement criteria and change in individual outcome measures. Logistic/linear regression models were fitted for response outcome. Results In the 3C and 2C models, patients with RA were 1.92 (CI: 1.04 to 3.54) and 2.03 (CI: 1.09 to 3.78) times more likely to be classified as EULAR responders if they had high (75th quartile) pre-treatment levels of MRP8/14 compared with low (25th quartile). No significant associations were observed for the 4C model. When only using CRP as a predictor, in the 3C and 2C analyses, patients above the 75th quartile were 3.79 (CI: 1.81 to 7.93) and 3.58 (CI: 1.74 to 7.35) times more likely to be EULAR responders and addition of MRP8/14 did not significantly improve model fit (p values=0.62 and 0.80, respectively). No significant associations were observed in the 4C analysis. Exclusion of CRP from the outcome measure (CDAI) did not result in any significant associations with MRP8/14 (OR 1.00 (CI: 0.99 to 1.01), suggesting that the associations were due to the correlation with CRP and that there is no additional utility of MRP8/14 beyond use of CRP in patients with RA starting TNFi therapy. Conclusion Beyond correlation with CRP, we found no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in patients with RA over and above CRP alone.
Physical Activity and Insulin Sensitivity Independently Attenuate the Effect of <i>FTO</i> rs9939609 on Obesity
Authors: Mette K. Andersen, Lars Ängquist, Jette Bork-Jensen, Anna E. Jonsson, Sara E. Stinson, Camilla H. Sandholt, Malte Thodberg, Laura Maarit Pikkupeura, Emily L. Ongstad, Niels Grarup, Arne Astrup, Oluf Pedersen, Kristine Williams, Romain Barrès, Thorkild I.A. Sørensen, Allan Linneberg, Joseph Grimsby, Christopher J. Rhodes, Torben Hansen
Journal: Diabetes Care (2023)

OBJECTIVE The association between FTO rs9939609 and obesity is modified by physical activity (PA) and/or insulin sensitivity (IS). We aimed to assess whether these modifications are independent, to assess whether PA and/or IS modify the association between rs9939609 and cardiometabolic traits, and to elucidate underlying mechanisms. RESEARCH DESIGN AND METHODS Genetic association analyses comprised up to 19,585 individuals. PA was self-reported, and IS was defined based on inverted HOMA insulin resistance index. Functional analyses were performed in muscle biopsies from 140 men and in cultured muscle cells. RESULTS The BMI-increasing effect of the FTO rs9939609 A allele was attenuated by 47% with high PA (β [SE], −0.32 [0.10] kg/m2, P = 0.0013) and by 51% with high IS (−0.31 [0.09] kg/m2, P = 0.00028). Interestingly, these interactions were essentially independent (PA, −0.20 [0.09] kg/m2, P = 0.023; IS, −0.28 [0.09] kg/m2, P = 0.0011). The rs9939609 A allele was also associated with higher all-cause mortality and certain cardiometabolic outcomes (hazard ratio, 1.07–1.20, P &amp;gt; 0.04), and these effects tended to be weakened by greater PA and IS. Moreover, the rs9939609 A allele was associated with higher expression of FTO in skeletal muscle tissue (0.03 [0.01], P = 0.011), and in skeletal muscle cells, we identified a physical interaction between the FTO promoter and an enhancer region encompassing rs9939609. CONCLUSIONS Greater PA and IS independently reduced the effect of rs9939609 on obesity. These effects might be mediated through altered expression of FTO in skeletal muscle. Our results indicated that PA and/or other means of increasing insulin sensitivity could counteract FTO-related genetic predisposition to obesity.
The immune‐supportive diet in allergy management: A narrative review and proposal
Authors: Berber Vlieg‐Boerstra, Marion Groetch, Emilia Vassilopoulou, Rosan Meyer, Kirsi Laitinen, Anne Swain, Raquel Durban, Olga Benjamin, Rachelle Bottse, Kate Grimshaw, Merryn Netting, Liam O'Mahony, Nicolette de Jong, Isabel J. Skypala
Journal: Allergy (2023)

Abstract The role of nutrition is increasingly recognized in the management of chronic immune diseases. However, the role of an immune‐supportive diet as adjuvant therapy in the management of allergic disease has not been similarly explored. This review assesses the existing evidence for a relationship between nutrition, immune function, and allergic disease from a clinical perspective. In addition, the authors propose an immune‐supportive diet to enhance dietary interventions and complementing other therapeutic options for allergic disease from early life to adulthood. A narrative review of the literature was conducted, to determine the evidence of the relationship between nutrition and immune function, overall health, epithelial barrier function, and gut microbiome, particularly in relation to allergy. Studies on food supplements were excluded. The evidence was assessed and utilized to develop a sustainable immune‐supportive diet to complement other therapies in allergic disease. The proposed diet consists of a highly diverse range of fresh, whole, and minimally processed plant‐based and fermented foods supplemented with moderate amounts of nuts, omega‐3‐rich foods and animal‐based products in proportional amounts of the EAT‐Lancet diet, such as (fatty) fish, (fermented) milk products which may be full‐fat and eggs, lean meat or poultry, which may be free‐range or organic.
Performance of the Dexcom G6 Continuous Glucose Monitoring System During Cardiac Surgery Using Hypothermic Extracorporeal Circulation
Authors: David Herzig, Martina Vettoretti, Dominik P. Guensch, Andreas Melmer, Daniel Schürch, Jonathan Roos, Arna M.C. Goerg, Gabija Krutkyte, Luca Cecchini, Andrea Facchinetti, Andreas P. Vogt, Lia Bally
Journal: Diabetes Care (2023)

OBJECTIVE Continuous glucose monitoring (CGM) may be challenged by extreme conditions during cardiac surgery using hypothermic extracorporeal circulation (ECC). RESEARCH DESIGN AND METHODS We evaluated the Dexcom G6 sensor in 16 subjects undergoing cardiac surgery with hypothermic ECC, of whom 11 received deep hypothermic circulatory arrest (DHCA). Arterial blood glucose, quantified by the Accu-Chek Inform II meter, served as reference. RESULTS Intrasurgery mean absolute relative difference (MARD) of 256 paired CGM/reference values was 23.8%. MARD was 29.1% during ECC (154 pairs) and 41.6% immediately after DHCA (10 pairs), with a negative bias (signed relative difference: −13.7%, −26.6%, and −41.6%). During surgery, 86.3% pairs were in Clarke error grid zones A or B and 41.0% of sensor readings fulfilled the International Organization for Standardization (ISO) 15197:2013 norm. Postsurgery, MARD was 15.0%. CONCLUSIONS Cardiac surgery using hypothermic ECC challenges the accuracy of the Dexcom G6 CGM although recovery appears to occur thereafter.